

Cite this: *Chem. Sci.*, 2015, 6, 2795

In vivo evaluation of small-molecule thermoresponsive anticancer drugs potentiated by hyperthermia

Catherine M. Clavel, Patrycja Nowak-Sliwinska, Emilia Păunescu, Arjan W. Griffioen and Paul J. Dyson*

Hyperthermia used as an adjuvant with chemotherapy is highly promising in the treatment of certain cancers. Currently, the small molecule drugs used in combination with hyperthermia were not designed for this application. Herein, we report the evaluation of a chlorambucil and a ruthenium compound modified with a long fluorinated chain, which exhibit thermoresponsive activity in colorectal adenocarcinoma xenografts in athymic mice in combination with mild hyperthermia (42 °C). Intraperitoneal injection of the derivatives followed by local hyperthermia showed a synergistic tumor growth reduction by 79% and 90% for the chlorambucil and ruthenium-based derivatives, respectively, with the latter exhibiting a higher synergy in combination with hyperthermia compared to the monotherapies. Histological analysis shows that both derivatives in combination with hyperthermia significantly decrease the number of proliferating tumor cells.

Received 17th February 2015

Accepted 17th March 2015

DOI: 10.1039/c5sc00613a

www.rsc.org/chemicalscience

Introduction

The most widely applied anticancer drugs tend to exhibit severe side-effects¹ and, consequently, considerable efforts have been directed towards the design of more selective anticancer drugs or treatment protocols that reduce side-effects and improve the quality of life of the patient, both during and after chemotherapy. It has been shown that combining chemotherapy with regional mild hyperthermia (applying heat locally to raise the tumor temperature between 40 and 42 °C), can sensitize tumor tissue to anticancer agents resulting in improved local control, treatment efficacy and overall survival prolongation.^{2,3} A promising approach used to enhance drug action when combined with hyperthermia is to employ drugs that are activated only under hyperthermia conditions.^{4,5}

Attaching known drugs to thermoresponsive macromolecules has led to hyperthermia treatments that are considerably more effective and selective than the application of the drug alone.^{6–11}

For example, doxorubicin has been extensively studied in liposomal formulations designed for thermoresponsive release,^{11,12} which also benefit from preferential accumulation in solid tumors due to the enhanced permeability and retention effect that relies on microvascular hyperpermeability to macromolecules.^{13–15} One such formulation termed ThermoDox[®] is based on a low temperature sensitive liposome

containing doxorubicin, which upon heating to 42 °C releases the doxorubicin.^{16,17} ThermoDox[®] is currently in phase III clinical trials in combination with radiofrequency ablation for the treatment of hepatocellular carcinoma.¹⁸

Hyperthermia used as an adjuvant with chemotherapy, but also with radiotherapy^{19,20} or their combination, also shows promise in cancer treatment. A triple therapy comprising radiotherapy, hyperthermia and chemotherapy, employing temozolomide (with liposomal doxorubicin included in resistant cases), led to enhanced survival rates in a glioblastoma clinical trial.²¹ In this study over 50% of patients showed prolonged survival to 26 months whereas the median survival following surgery is usually less than 4 months, which slightly increases with radiotherapy.^{22,23} Chlorambucil has also been encapsulated in a biodegradable and thermoresponsive micellar system based on triblock copolymers that increase water solubility and control its release near the tumor.^{24,25}

Methods to transform anticancer drugs such as doxorubicin, chlorambucil, cisplatin and other compounds into thermoresponsive agents focus mainly on the use of macromolecules, notably liposomal formulations, or magnetic nanoparticles that encapsulate the drug and deliver it at the tumor site under hyperthermia.^{26–31} Nevertheless, replacing macromolecules with low molecular weight thermosensitive drugs remains an attractive alternative option due, in part, to the variability and complexity of nanoscale medicines.

We have recently shown that perfluorinated chains covalently bound to small molecule drugs give rise to thermoresponsive solubility, *i.e.* low solubility that rapidly increases with small increases in temperature, with the change in solubility

Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. E-mail: paul.dyson@epfl.ch; Fax: +41 21 693 97 80; Tel: +41 21 693 98 54





Fig. 1 Chemical structures of chlorambucil, RAPTA-C and the thermoactive derivatives 1 and 2.

being considerably greater than that of the parent drug. A modified chlorambucil derivative **1**³² and a monofunctional RAPTA-C like ruthenium(II) compound **2**³³ (see Fig. 1) are essentially non-cytotoxic at 37 °C and highly cytotoxic to cancer cells when activated by a 2 hour hyperthermia signal (41.5 °C). In this study, compounds **1** and **2** were evaluated in a pre-clinical model in combination with mild hyperthermia validating their synergy in cancer treatment *in vivo*.

Results and discussion

Human adenocarcinoma LS174T cells were implanted subcutaneously on the hind leg of athymic mice, as local mild hyperthermia can easily be applied at this site, and were allowed to grow until a palpable tumor mass was observed. The compounds (**1** or **2**) were injected intraperitoneally (i.p.) at a dose of 12.5 mg per kg per day in a 10% DMSO solution in sterile saline (0.9% NaCl) with control groups receiving a 10% DMSO saline solution. In parallel monotherapy groups with hyperthermia treatment only (30 minutes at 42 °C) or **1** or **2** only

were studied. Dual therapy was performed by injection of the compound followed by hyperthermia treatment with a drug-hyperthermia interval of a maximum of 15 minutes. The rapid induction of hyperthermia following drug injection was shown to be optimal for several clinically approved drugs, *e.g.* cisplatin, melphalan and carboplatin.^{34–37}

Tumor growth was measured daily starting at the first day of treatment (day 6, following inoculation on day 0). The median tumor volume of each group for **1** is shown in Fig. 2.

Significant tumor inhibition from day 7 to 18 is observed (based on ANOVA testing). In addition, post ad-hoc statistical analysis using the one-sided pairwise *t*-test indicates that **1** alone ($p = 0.00184$), hyperthermia alone ($p = 0.00610$) and the duotherapy of **1** + hyperthermia ($p = 3.2 \times 10^{-4}$) significantly reduce tumor growth compared to the control group. Indeed, on the last day of the experiment, duotherapy gives a drug efficacy of 79% versus 59% (for **1** alone) and 45% (for hyperthermia alone), with the **1** + hyperthermia duotherapy acting synergistically on tumor growth reduction following the fractional product, $DE_{1,H} = 0.787$ (see Experimental). It should be noted



Fig. 2 LS174T adenocarcinoma growth inhibition in athymic mice. Mice were treated with **1** (12.5 mg kg⁻¹, 300 μ L i.p.) given every 4 days (indicated by the green arrows) with or without mild hyperthermia (42 °C for 30 minutes) within 15 minutes following drug injection. The control group animals were treated with 10% DMSO in sterile saline (0.9% NaCl) also given every 4 days. Results are expressed as medians \pm the standard error of the mean, SEM ($n = 5$ to 8 mice/group, ANOVA, $**p < 0.01$, $***p < 0.001$), efficacy $DE_{1,H} = 0.787$. Tumor volume (mm³) was calculated using the formula: volume = width² \times length \times 0.5.






Fig. 3 LS174T adenocarcinoma growth inhibition in athymic mice. Mice were treated with **2** (12.5 mg kg^{-1} , $300 \mu\text{L}$ i.p.) given every 4 days (indicated by green arrows) with or without mild hyperthermia ($42 \text{ }^\circ\text{C}$ for 30 minutes) administered intraperitoneally. The vehicle control was treated with three doses of 10% DMSO in sterile saline (0.9% NaCl) also given every 4 days. Values plotted are medians \pm the standard error of the mean, SEM ($n = 5\text{--}8$ mice per group, ANOVA, $**p < 0.01$, $***p < 0.001$), efficacy $DE_{2,H} = 0.899$.

that hyperthermia alone has previously been shown to reduce tumor size in patients,³⁸ as cancer cells are more sensitive than normal cells to mild hyperthermia ($41\text{--}43 \text{ }^\circ\text{C}$).^{39,40}

The same *in vivo* model was also used to evaluate in duotherapy **2** with hyperthermia on tumor growth reduction (Fig. 3) using the protocol described for **1**. ANOVA testing confirmed significant tumor growth reduction and post *ad hoc* statistical analysis using the one-sided pairwise *t*-test gave significant differences in tumor growth for **2** alone ($p = 0.0013$), hyperthermia alone (30 minutes at $42 \text{ }^\circ\text{C}$, $p = 0.0058$) and **2** + hyperthermia ($p = 7.4 \times 10^{-5}$) compared to the control group. Moreover, the tumor volume in the mice undergoing duotherapy is significantly different from hyperthermia alone and from **2** given as a monotherapy ($*p\text{-values} < 0.05$). Compound **2** inhibited tumor growth by 66%, whereas the duotherapy of **2** +

hyperthermia resulted in tumor growth inhibition of 90%, with the combination displaying strong synergistic effects ($DE_{2,H} = 0.899$).

In order to detect proliferating cells, treated tumor tissue sections from the various studies were stained with the nuclear proliferation marker Ki67 (Fig. 4). Hyperthermia by itself showed an anticancer effect, decreasing the number of proliferating cells by 33% ($p = 0.0462$). The application of **1** or **2** both significantly reduces the number of proliferating cells (28%, $p = 0.041$ and 37%, $p = 0.0465$, respectively). Duotherapy of **1** + hyperthermia resulted in a 84% decrease of proliferating cells ($p = 0.0037$), whereas **2** + hyperthermia inhibited proliferating tumor cells by 91%, *i.e.* inducing an enhanced state of quiescence. This cellular quiescence, or proliferation arrest, presumably represents a homogeneous state induced by diverse




Fig. 4 Histochemical analysis of tumors stained for proliferating cells (Ki67). Representative sections of tumors of the different treatment groups are shown. Ki67 + nuclei are indicated with red arrows. Scale bar = $100 \mu\text{m}$ (left). Quantification of proliferating tumor cells per treatment group, errors are shown as means \pm the standard error of the mean (right).






Fig. 5 Histochemical analysis of tumor necrosis using hematoxylin and eosin (H&E) staining. Representative sections of tumors from different treatment groups are shown. Tumor necrosis is observed in the hyperthermia group and is extensive in the 2 + hyperthermia group (indicated by the black arrows). Scale bar = 100 μm .




Fig. 6 Ruthenium content in tissues (ng mg^{-1} of wet tissue) after mouse sacrifice for 2 applied as a monotherapy and 2 used in duotherapy with hyperthermia. Values are means \pm SEM.

anti-mitogenic signals.⁴¹ Previously, it was shown that RAPTA-C treated mice bearing LS174T tumors leads to similar effects,⁴² however, RAPTA-C was administered daily at 100 mg kg^{-1} , an 8-fold higher dose than 2 (12.5 mg kg^{-1} given every 4 days). Hyperthermia combined with known chemotherapy agents has previously been shown to lead to some necrosis,⁴³ which was also observed with 1 and 2 (Fig. 5). However, with these specially-designed thermoactive compounds, antiproliferative activity is efficiently triggered by a short mild hyperthermia signal without apparently affecting the surrounding tissues, therefore providing enhanced selectivity.

Treatment toxicity and side-effects of the monotherapies and duotherapy were assessed by monitoring the relative body-weight of the mice on daily basis. At the end of the experiment the average body weight of the mice was not significantly different between all the treatment groups. At a behavioral level no unusual changes were observed including no change in food and water intake throughout the experiment period. Moreover, acute induction of inflammation of the tumors was not observed. Since ruthenium is not naturally present in living organisms, the distribution of ruthenium in tissues was

determined after sacrificing mice treated with either 2 alone or in duotherapy. Organs were removed and dried, digested in nitric acid, and their ruthenium content determined by ICP-MS (Fig. 6).

Ruthenium accumulates in the kidneys, an organ associated with penetration and elimination of drugs, similar to that observed for the antimetastatic ruthenium(III) drug NAMI-A, which accumulates in kidneys in a dose-dependent manner,⁴⁴ and in RAPTA-C-treated mice.⁴² Ruthenium also accumulates in the liver, but two fold less than in kidneys, followed by the stomach and spleen. The concentration of ruthenium in the lungs is low, in contrast to NAMI-A, which exhibits equivalent concentrations in lungs, kidneys and liver.⁴⁵ Notably, duotherapy with hyperthermia does not significantly affect the ruthenium distribution in the organs.

Conclusions

We have validated the concept of using small molecule thermoresponsive compounds in combination with hyperthermia to inhibit tumor growth. Two very different classes of drugs with



perfluorinated chains were studied, with the perfluorinated chain endowing the compounds with thermomorphic properties. Compound **1**, which is derived from the alkylating agent chlorambucil, and **2**, which is structurally related to a compound that selectively targets histone proteins in chromatin,^{46,47} exhibit a synergistic tumor growth reduction in duotherapy with local hyperthermia, with **2** showing a higher synergistic level with hyperthermia than **1**, and resulting in a 90% reduction of tumor growth. Attempts were not made to elucidate the biomolecular targets of **1** and **2**, however, it is not unreasonable to assume that **1**, like chlorambucil, targets DNA (since the fluorinated chain can be lost following cellular uptake), and that **2** may behave in the same way as other bifunctional ruthenium(II)-arene compounds.^{47,50} Notably, duotherapy decreases the number of proliferating cancer cells and enhances tumor necrosis in the absence of systemic damage to the surrounding tissues and organs. These findings not only validate the strategy, but also indicate more generally that drug modification with perfluorinated chains may enhance tumor growth inhibition efficacy without inducing additional side-effects, and could be applied to other drugs currently used in the clinic to treat cancer.

Experimental

Compounds **1** and **2** were prepared as described previously.^{32,33} Compounds were dissolved in DMSO (Sigma-Aldrich) and diluted to a final concentration of 12.5 mg kg⁻¹ in sterile saline (0.9% NaCl) prior i.p. injections. The control group animals were treated with 10% DMSO in sterile saline (0.9% NaCl) also given every 4 days.

Cell implantation in athymic mice and treatment protocol

Experiments in 8 week old Swiss female athymic mice purchased from Charles River (Orleans, France) were carried out according to a protocol approved by the Committee for Animal Experiments for the Canton of Vaud, Switzerland (license 2772). LS174T colorectal adenocarcinoma cells (Cell Line Service GmbH, Eppelheim, Germany) were cultured in DMEM culture medium (Gibco, Carlsbad, USA) supplemented with 10% heat-inactivated fetal calf serum and 1% antibiotics (Sigma-Aldrich, St. Luis, USA). Mice were injected subcutaneously in the hind left leg with 5×10^5 LS174T cells resuspended in culture medium. When tumors reached a size of 5–6 mm in diameter, *i.e.* on day 6, mice received 12.5 mg kg⁻¹ of either **1** or **2** in 10% DMSO in saline as 300 μ L i.p. injection with or without hyperthermia (30 minutes at 42 °C, drug-heat interval of <15 minutes). Commercially available heating pads (Thermopad, 10200034 type 226, Solis AG – Switzerland, 30 × 40 cm heated pad, with 100 watt output and 6 temperature settings) to locally heat a subcutaneous tumor in the hind leg were used. To minimize the stress due to hyperthermia treatment immobilization anesthesia was carried out under 2.5% isoflurane and kept under 1.5% of isoflurane for the duration of the experiment with a humidified isoflurane system (Rothhacher GmbH, Bern, Switzerland). This treatment was repeated following the

q4d3 schedule, *i.e.* a total of 3 doses at 4 day intervals. Tumor dimensions and body weight were measured daily. Tumor volumes (mm³) were calculated using the following formula volume = width² × length × 0.5. At the end of the experiment, when the control tumor size reached 1000 mm³ the mice were euthanized and the tumors resected and fixed in formalin solution for immunohistochemistry. Blood, part of tumors and organs were snap-frozen for ruthenium distribution measurements.

Immunohistochemistry

Tumor sections (5 μ m) were blocked with 5% BSA in PBS and incubated with primary antibodies against Ki-67 (mouse anti-human Ki-67; 1 : 200, clone 1A4, Dako, Gostrup, Denmark). This step was followed by the addition of alkaline phosphatase conjugated polymer Mach 2 (Biocare Medical, Concord, USA) and visualized by Fast Blue BB/Naphthol-AS-MX-Phosphate, resulting in a blue/purple-colored precipitate. Hematoxylin and eosin staining was routinely performed. Briefly, sections were deparaffinized in xylene I, II and III, washed and stained in hematoxylin (Harris Hematoxylin, Sigma) followed by eosin staining. In the next step they were dehydrated by washing in ethanol and mounted with DPX mountant and coverslip. Sections were imaged using Olympus microscope IX81 connected to Leica 200 scientific camera.

Drug distribution measurements

Tissues of interest were collected, weight and dried until their weight remained constant. Samples were digested in concentrated nitric acid (1 mL) for 2 days. Samples were completed to a total volume of 8 mL with water. Indium was added as an internal standard at a concentration of 0.5 ppb. Determination of the metal content was achieved using an Elan DRC II ICP-MS instrument (Perkin-Elmer, Switzerland) equipped with a Meinhard nebulizer and a cyclonic spray chamber. The ICP-MS instrument was tuned using a solution containing 1 ppb of the following elements: Mg, In, Ce, Ba, Pb and U. External standards were prepared gravimetrically in an identical matrix to the samples with single element standards obtained from CPI International (Amsterdam, The Netherlands). Values were normalized per mg of wet tissue.

Drug efficacy and synergy calculation

Drug efficacy (DE), or tumor regression, was calculated from the tumor growth of the treated group (*T*) and the control group (*C*) using the relation: $DE = 1 - T/C$. A synergy between the drug and hyperthermia was calculated with the fractional product method (for independent inhibitors).⁴⁸ Limited to the final dose-point, the isobologram resulting from the Chou–Talalay combination index method cannot be built since it needs two points for each monotherapy. Nevertheless, the fractional product gives a first insight at the synergistic level between **1** and hyperthermia with the formula: $f_{1,H} = f_1 \times f_{1,H}$, where $f_{1,H}$, f_1 , and $f_{1,H}$ are fractions of the total activity unaffected by the combination of **1** + hyperthermia, **1** and hyperthermia, respectively. Using drug efficacy (tumor reduction) values from the



tumor growth curves: $f_1 \times f_H = (1 - DE_1)(1 - DE_H) = 0.226$. Therefore, the combination 1 with hyperthermia was considered as synergistic if: $DE_{1,H} > 1 - 0.226 = 0.774$, which was the case as $DE_{1,H} = 0.787$. In the same way, for a synergistic effect between 2 with hyperthermia the value must be higher than: $1 - (1 - DE_2)(1 - DE_H) = 0.812$, where $DE_2 = 0.656$ and $DE_H = 0.454$, which was the case as $DE_{2,H} = 0.899$.

Toxicity evaluation

To monitor the toxicity during the treatment the mice were observed daily in terms of relevant indexes such as body weight, appearance, provoked and natural behavior change and food and water intake.

Statistical analysis

Tumor growth values are given as median values \pm standard error of the mean. Statistical analysis was conducted using the R software (version 3.1.0).⁴⁹ ANOVA tests were used to assess the significance of results and were accompanied by one-sided pairwise *t*-test ad-hoc analysis. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Acknowledgements

We thank the Swiss National Science Foundation and EPFL for financial support and Dr Andrea Weiss for maintenance of the LS174T cells.

References

- 1 T. Henne and D. Schmhil, *Cancer Treat. Rev.*, 1985, **12**, 77–94.
- 2 R. D. Issels, L. H. Lindner, J. Verweij, P. Wust, P. Reichardt, B. C. Schem, S. Abdel-Rahman, S. Daugaard, C. Salat, C. M. Wendtner, Z. Vujaskovic, R. Wessalowski, K. W. Jauch, H. R. Durr, F. Ploner, A. Baur-Melnyk, U. Mansmann, W. Hiddemann, J. Y. Blay and P. Hohenberger, *Lancet Oncol.*, 2010, **11**, 561–570.
- 3 K. Pietzner, R. B. Schmuck, C. Fotopoulou, J. Gellermann, F. Ismael, C. H. Cho, M. Kalden and J. Sehouli, *Anticancer Res.*, 2011, **31**, 2675–2677.
- 4 R. D. Issels, *Eur. J. Cancer*, 2008, **44**, 2546–2554.
- 5 A. Chilkoti, M. R. Dreher, D. E. Meyer and D. Raucher, *Adv. Drug Deliver. Rev.*, 2002, **54**, 613–630.
- 6 L. Li, T. L. ten Hagen, D. Schipper, T. M. Wijnberg, G. C. van Rhooon, A. M. Eggermont, L. H. Lindner and G. A. Koning, *J. Controlled Release*, 2010, **143**, 274–279.
- 7 D. Needham, G. Anyarambhatla, G. Kong and M. W. Dewhirst, *Cancer Res.*, 2000, **60**, 1197–1201.
- 8 L. H. Lindner, M. E. Eichhorn, H. Eibl, N. Teichert, M. Schmitt-Sody, R. D. Issels and M. Dellian, *Clin. Cancer Res.*, 2004, **10**, 2168–2178.
- 9 A. M. Ponce, Z. Vujaskovic, F. Yuan, D. Needham and M. W. Dewhirst, *Int. J. Hyperthermia*, 2006, **22**, 205–213.
- 10 S. Unezaki, K. Maruyama, N. Takahashi, M. Koyama, T. Yuda, A. Suginaka and M. Iwatsuru, *Pharm. Res.*, 1994, **11**, 1180–1185.
- 11 G. Kong, G. Anyarambhatla, W. P. Petros, R. D. Braun, O. M. Colvin, D. Needham and M. W. Dewhirst, *Cancer Res.*, 2000, **60**, 6950–6957.
- 12 Y. Min, C.-Q. Mao, S. Chen, G. Ma, J. Wang and Y. Liu, *Angew. Chem., Int. Ed.*, 2012, **51**, 6742–6747.
- 13 H. Maeda, H. Nakamura and J. Fang, *Adv. Drug Deliver. Rev.*, 2013, **65**, 71–79.
- 14 H. Maeda, *Bioconjugate Chem.*, 2010, **21**, 797–802.
- 15 A. K. Iyer, G. Khaled, J. Fang and H. Maeda, *Drug Discovery Today*, 2006, **11**, 812–818.
- 16 J. K. Mills and D. Needham, *Methods Enzymol.*, 2004, **387**, 82–113.
- 17 M. L. Hauck, S. M. LaRue, W. P. Petros, J. M. Poulson, D. Yu, I. Spasojevic, A. F. Pruitt, A. Klein, B. Case, D. E. Thrall, D. Needham and M. W. Dewhirst, *Clin. Cancer Res.*, 2006, **12**, 4004–4010.
- 18 D. Needham, in *Biomaterials for cancer therapeutics : diagnosis, prevention, and therapy*, ed. K. Park, Woodhead Publishing Series in Biomaterials, Oxford, 2013, ch. 12, vol. 66, pp. 270–348.
- 19 M. Franckena, *Int. J. Hyperthermia*, 2012, **28**, 543–548.
- 20 T. M. Zagar, J. R. Oleson, Z. Vujaskovic, M. W. Dewhirst, O. I. Craciunescu, K. L. Blackwell, L. R. Prosnitz and E. L. Jones, *Int. J. Hyperthermia*, 2010, **26**, 618–624.
- 21 G. Baronzio, G. Parmar, M. De Santis and A. Gramaglia, in *Cancer Treatment – Conventional and Innovative Approaches*, ed. L. Rangel, InTech, 2013, ch. 13, pp. 285–296.
- 22 K. Nakagawa, Y. Aoki, T. Fujimaki, M. Tago, A. Terahara, K. Karasawa, K. Sakata, Y. Sasaki, M. Matsutani and A. Akanuma, *Int. J. Radiat. Oncol., Biol., Phys.*, 1998, **40**, 1141–1149.
- 23 P. J. Miller, R. S. Hassanein, P. G. Giri, B. F. Kimler, P. O'Boynick and R. G. Evans, *Int. J. Radiat. Oncol., Biol., Phys.*, 1990, **19**, 275–280.
- 24 V. San Miguel, A. J. Limer, D. M. Haddleton, F. Catalina and C. Peinado, *Eur. Polym. J.*, 2008, **44**, 3853–3863.
- 25 J. Woo, G. N. C. Chiu, G. Karlsson, E. Wasan, L. Ickenstein, K. Edwards and M. B. Bally, *Int. J. Pharm.*, 2008, **349**, 38–46.
- 26 K. Kakinuma, R. Tanaka, H. Takahashi, Y. Sekihara, M. Watanabe and M. Kuroki, *Int. J. Hyperthermia*, 1996, **12**, 157–165.
- 27 R. T. P. Poon and N. Borys, *Expert Opin. Pharmacother.*, 2009, **10**, 333–343.
- 28 N. Andhariya, B. Chudasama, R. V. Mehta and R. V. Upadhyay, *J. Nanopart. Res.*, 2011, **13**, 1677–1688.
- 29 K. Iga, N. Hamaguchi, Y. Igari, Y. Ogawa, K. Gotoh, K. Ootsu, H. Toguchi and T. Shimamoto, *J. Pharmacol. Exp. Ther.*, 1991, **257**, 1203–1207.
- 30 A. A. Petryk, A. J. Giustini, R. E. Gottesman, P. A. Kaufman and P. J. Hoopes, *Int. J. Hyperthermia*, 2013, **29**, 845–851.
- 31 M. P. Alvarez-Berrios, A. Castillo, J. Mendez, O. Soto, C. Rinaldi and M. Torres-Lugo, *Int. J. Nanomed.*, 2013, **8**, 1003–1013.
- 32 C. M. Clavel, O. Zava, F. Schmitt, B. H. Kenzaoui, A. A. Nazarov, L. Juillerat-Jeanneret and P. J. Dyson, *Angew. Chem., Int. Ed.*, 2011, **50**, 7124–7127.



- 33 C. M. Clavel, E. Păunescu, P. Nowak-Sliwinska and P. J. Dyson, *Chem. Sci.*, 2014, **5**, 1097–1101.
- 34 J. B. Marmor, *Cancer Res.*, 1979, **39**, 2269–2276.
- 35 O. Dahl and O. Mella, *Anticancer Res.*, 1982, **2**, 359–364.
- 36 J. Overgaard, *Int. J. Radiat. Oncol., Biol., Phys.*, 1989, **16**, 535–549.
- 37 P. L. Ausmus, A. V. Wilke and D. L. Frazier, *Cancer Res.*, 1992, **52**, 4965–4968.
- 38 R. Cavaliere, E. C. Ciocatto, B. C. Giovanella, C. Heidelberger, R. O. Johnson, M. Margottini, B. Mondovi, G. Moricca and A. Rossi-Fanelli, *Cancer*, 1967, **20**, 1351–1381.
- 39 K. Overgaard and J. Overgaard, *Eur. J. Cancer*, 1972, **8**, 65–78.
- 40 R. T. Pettigrew, J. M. Galt, C. M. Ludgate and A. N. Smith, *Br. Med. J.*, 1974, **4**, 679–682.
- 41 H. A. Collier, L. Sang and J. M. Roberts, *PLoS Biol.*, 2006, **4**, e83.
- 42 A. Weiss, B. H. Berndsen, M. Dubois, M. Müller, R. Schibli, A. W. Griffioen, P. J. Dyson and P. Nowak-Sliwinska, *Chem. Sci.*, 2014, **5**, 4742–4748.
- 43 W. Nie, X. L. Ma, Y. X. Sang, Y. L. Li, X. Gao, G. C. Xu, G. B. Shen, H. S. Shi, X. X. Liu, F. T. Wang and Y. Q. Wei, *Clin. Exp. Med.*, 2014, **14**, 203–213.
- 44 S. Zorzet, A. Sorc, C. Casarsa, M. Cocchietto and G. Sava, *Met.-Based Drugs*, 2001, **8**, 1–7.
- 45 M. Cocchietto and G. Sava, *Pharmacol. Toxicol.*, 2000, **87**, 193–197.
- 46 B. Wu, M. S. Ong, M. Groessler, Z. Adhireksan, C. G. Hartinger, P. J. Dyson and C. A. Davey, *Chem.–Eur. J.*, 2011, **17**, 3562–3566.
- 47 Z. Adhireksan, G. E. Davey, P. Campomanes, M. Groessler, C. M. Clavel, H. J. Yu, A. A. Nazarov, C. H. F. Yeo, W. H. Ang, P. Droge, U. Rothlisberger, P. J. Dyson and C. A. Davey, *Nat. Commun.*, 2014, **5**, 3462.
- 48 A. Ocana, E. Amir, C. Yeung, B. Seruga and I. F. Tannock, *Ann. Oncol.*, 2012, **23**, 2161–2166.
- 49 R Core Team, *R Foundation for Statistical Computing*, Vienna, Austria, 3.1.0 edn, 2014.
- 50 M. V. Babak, S. M. Meier, K. Huber, J. Reynisson, A. A. Legin, M. A. Jakupec, A. Roller, A. Stukalov, M. Gridling, K. L. Bennett, J. Colinge, P. J. Dyson, G. Superti-Furga, B. K. Keppler and C. G. Hartinger, *Chem. Sci.*, 2015, **6**, 2449–2456.

